Research programme: anti-PcrV and anti-PcrV/Psl monoclonal antibodies - MedImmune

Drug Profile

Research programme: anti-PcrV and anti-PcrV/Psl monoclonal antibodies - MedImmune

Alternative Names: 166; MS1; MS2; MS3

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Bacterial polysaccharide inhibitors; PcrV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Pseudomonal infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pseudomonal-infections(Prevention) in USA (Parenteral)
  • 12 Sep 2012 Preclinical trials in Pseudomonal infections (prevention) in USA (Parenteral)
  • 12 Sep 2012 Pharmacodynamics data from preclinical trials in Pseudomonal infections presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top